Doctors often struggle to find the right treatment for brain bleeding. Standard tests and single markers do not capture the full picture of how the brain reacts. This review highlights that current monitoring strategies fail to see the dynamic network of chemical changes that drive injury. Single biomarkers are easily confused by general inflammation in the body. Conventional imaging also lacks the molecular sensitivity needed to see early damage.
A new approach combines iron metabolism with inflammatory markers, brain-derived exosomes, and quantitative susceptibility mapping. This multidimensional framework offers a clearer view than old methods. It helps doctors understand the specific chemical environment in each patient. This clarity is vital for deciding who will benefit from iron chelation or anti-ferroptotic therapies.
The review notes that current tools are not sensitive enough for these complex cases. It does not report safety data because this is a review of existing ideas, not a clinical trial. However, the potential to stratify patients is clear. Better monitoring could lead to more precise care for those with intracerebral hemorrhage.